ABSTRACT Three peptides corresponding to fragments of diphtheria toxin have been synthesized. They include the previously described tetradecapeptide and two structural analogs, the hexadecapeptide and the octadecapeptide. Conjugates of these peptides to proteins or a synthetic carrier have induced in guinea pig protection against the dermonecrotic activity of diphtheria toxin. All ofthe conjugates were immunogenic when administered either in complete Freund's adjuvant or with N-acetylmuramyl-Lalanyl-D-isoglutamine in aqueous medium. Positive immune response toward the octadecapeptide was obtained in mice as well. In this case, the immunogenic combinations were conjugates with bovine serum albumin administered either in Freund's adjuvant or with the muramyl dipeptide and a complete synthetic conjugate comprising both the octadecapeptide and the muramyl dipeptide covalently attached to a synthetic carrier, multichain poly(DIAla). This last immunogen, which induced the most effective immune response, is a completely synthetic immunogen with built-in adjuvanticity and induces protective antitoxic immunity when administered in a physiological medium.
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The synthetic approach to vaccination has as its purpose the replacement ofclassical vaccines or the development ofvaccines not yet available. For this purpose, such a vaccine should contain a synthetic specific antigenic determinant as well as adequate adjuvanticity (1, 2) . For protein antigens, steric conformation is ofutmost importance for their specificity, and we have shown previously that it is possible to synthesize a peptide, denoted "loop," analogous to an immunopotent conformationdependent region ofthe hen eggwhite enzyme lysozyme, attach it to a polymeric synthetic carrier, and provoke conformationspecific antibodies in experimental animals (3) . This approach has been extended to other systems, and recently we reported the formation of antibodies toward a synthetic antigen containing a peptide derived from the coat protein ofa bacteriophage,  that were capable of efficiently neutralizing the virus (4) .
We have also previously reported that active antitoxic immunization against diphtheria can be achieved with a synthetic peptide covalently attached to a protein carrier (5) . This peptide, a tetradecapeptide denoted STDP, consists of residues 188-201 ( Fig. 1) in the amino acid sequence of the diphtheria toxin, and it represents a fragment of the loop (16 amino acid residues, 186-201, sustained by two cysteine residues) that comprises the two functional segments ofthe natural diphtheria toxin molecule (6, 7) . In all these studies, immunization was carried out in Freund's complete adjuvant (FCA) .
Earlier studies have shown that it is possible to obtain a high level ofantibody response to several antigens by using, instead of FCA, Freund's incomplete adjuvant (FIA) mixed with some of the peptidoglycan components of the bacterial cell wall, or subunits of them, including N-acetylmuramyl-L-alanyl-D-isoglutamine (8) (9) (10) (11) . The latter molecule, denoted muramyl dipeptide (MDP), and several of its derivatives, strongly enhanced the humoral antibody response to bovine serum albumin even when administered in saline (12) . This adjuvant activity was confirmed by using various bacterial, viral, or parasitic vaccines (13) (14) (15) (16) (17) (18) (19) . When covalently attached to the macromolecular antigens, the soluble adjuvants show higher activity. This was demonstrated with the MDP conjugate ofthe synthetic antigen poly(LTyr,LGlu)-poly(DLAla)--poly(LLys) (20) and with the poly(DLAla)--poly(LLys) (A--L) conjugate of the synthetic P2 peptide of MS-2 bacteriophage, using either the natural peptidoglycan (21) or synthetic MDP (22) . All these conjugates possessed built-in adjuvanticity leading to high level antibody production; thus, MDP-P2-A--L constitutes a completely synthetic material that induces antiviral activity even when administered in saline (22) .
Here 
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The publication costs ofthis article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U. S. C. §1734 solely to indicate this fact. (ii) MDP and SODP(SH)COOH were linked to A--L by using soluble carbodiimide, under the conditions described in ref. 23 and following the procedure of Goodfriend et aL (24) . When MDP-peptide-A--L conjugates were prepared, the first step was always the synthesis of MDP-A--L.
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(iii) To polymerize peptides, the conditions were as described below for carboxamidomethyl ( The protective activity of the antibodies elicited after immunization by various fragments was tested by measuring neutralization of the dermonecrotic activity of diphtheria toxin by several individual sera. Results can be summarized as follows: (i) there was a correlation between the antibody titer and the protective activity of the serum; (ii) high titers produced by all synthetic fragments conjugated to protein or synthetic carrier and administered with FCA could neutralize 50 MRD of toxin. Polymerized STDP associated with MDP in saline also neutralized 50 MRD of toxin. Serum of guinea pigs treated by SODP-A--L associated with MDP in saline, which had a lower antibody titer, neutralized only 25 MRD (Table 2) .
Antibody Response of Mice to Free or Conjugated SODP Administered with or without Adjuvants. The results are summarized in Table 3 . (i) When SODP was administered without a carrier in FCA or in Pi/NaCl with or without MDP, no antibodies were detectable. (ii) SODP conjugated to A--L but administered without an adjuvant was also devoid of immunogenicity. (iii) In contrast, SODP conjugated to bovine serum albumin and administeredwith FCA orwith MDP in saline gave detectable antibodies. Moreover, when both MDP and the antigenic peptide were coupled to a synthetic carrier and administered in aqueous solution, the responses were stronger than those observed with SODP-bovine serum albumin administered with FCA. The immune response was evoked both by conjugates in which the peptide was attached via the amino group and by those in which the linkage was via the carboxyl group. DISCUSSION Production of synthetic vaccines is desirable because this approach should lead to safer and more abundant sources of antigen and to less demanding quality control procedures. This is especially true for those viral vaccines (26) for which efficient procedures for in vitro culturing and vaccine preparation are not available. For the synthesis of such immunogens, knowledge of the viral structure is required, and this knowledge should also allow a better understanding of the mechanisms in- Table 2 . Protective activity of guinea pig anti-peptide sera against the dermonecrotic effect of diphtheria toxin Immunizing preparation volved in the immunity against immunopotent segments.
In the past, the use ofwell-defined haptens and antigens has contributed greatly to the advance of various aspects of basic immunology (27) . Immunization with artificial antigens and other chemically defined antigens has led to induction of antibodies reactive against intact native proteins. But, until recently, it was not clear whether in vivo production against complex bacterial or viral agents could be achieved with such synthetic antigens or whether the use of more complex multideterminant antigenic structures would be required. Early findings by Avery and Goebel (28, 29) showed that immunization with some pneumococcal oligosaccharides can provide protection against pneumonia. These, however, comprised short fragments ofrepeating sequences ofthe capsular polysaccharides. Recently, these findings were confirmed and expanded by the use of synthetic peptides. These studies include our report on the use of synthetic peptides that copy a region in diphtheria toxin (5, §) and one describing a study in which streptococcal antigens were used (30) . A synthetic conjugate has elicited neutralizing antibodies against a bacteriophage (21) . Several synthetic hepatitis B peptides were reported to elicit antibodies that can bind to the infective Dane particles of the virus, but their protective capacity in vivo has not yet been demonstrated (31) (32) (33) (34) (35) . Very recently, we reported the synthesis of a peptide fragment of influenza hemagglutinin, a conjugate of which induces antibodies reactive with the intact virus and inhibits its hemagglutinin activity and plaque formation in vitro; moreover, immunization ofmice with this conjugate led to their partial protection against challenge infection (36) .
All these studies, including our own, were achieved, however, by administering the antigen in FCA and, in most cases, when conjugated to a protein carrier. Only in the case of MS-2 coliphage were neutralizing antibodies induced by immunization in aqueous medium, by using a conjugate containing both the specific antigenic peptide and MDP. To our knowledge, the data reported here provide the first report of effective protective immunization against disease-causing bacteria with a totally synthetic vaccine in the absence of Freund's adjuvants. These results were obtained by attachment of various synthetic diphtheria peptides to a synthetic carrier conjugated to a synthetic adjuvant. In one instance, a polymerized peptide associated with MDP was capable ofinducing protection with no requirement for a carrier.
The titers reported here were rather low, but they are highly significant. Studies in which other synthetic vaccines 
